NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

$115.69

-0.01 (-0.01%)

(As of 09/28/2023 ET)

Compare

Today's Range: $115.66
▼
$115.80
50-Day Range: $98.98
▼
$115.74
52-Week Range: $60.03
▼
$115.87

Volume: 1.25 million shs
Average Volume: 3.35 million shs
Market Capitalization: $26.49 billion

P/E Ratio: 61.87
Dividend Yield: N/A
Price Target: $110.71

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 4.3% Downside
$110.71 Price Target
Short Interest: Healthy
3.10% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.97
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 42.19%
From $4.29 to $6.10 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

434th out of 969 stocks

Pharmaceutical Preparations Industry

191st out of 453 stocks

1.0

Analyst's Opinion

Consensus Rating
Horizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $110.71, Horizon Therapeutics Public has a forecasted downside of 4.3% from its current price of $115.69.
Amount of Analyst Coverage
Horizon Therapeutics Public has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.10% of the outstanding shares of Horizon Therapeutics Public have been sold short.
Short Interest Ratio / Days to Cover
Horizon Therapeutics Public has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Horizon Therapeutics Public has recently decreased by 25.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Horizon Therapeutics Public does not currently pay a dividend.
Dividend Growth
Horizon Therapeutics Public does not have a long track record of dividend growth.

3.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Horizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Horizon Therapeutics Public is -2.61.

2.8

News and Social Media Coverage

News Sentiment
Horizon Therapeutics Public has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Horizon Therapeutics Public this week, compared to 5 articles on an average week.
Search Interest
Only 8 people have searched for HZNP on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Horizon Therapeutics Public is held by insiders.
Percentage Held by Institutions
80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Horizon Therapeutics Public are expected to grow by 42.19% in the coming year, from $4.29 to $6.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Horizon Therapeutics Public is 61.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03.
Price to Earnings Ratio vs. Sector
The P/E ratio of Horizon Therapeutics Public is 61.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.52.
Price to Earnings Growth Ratio
Horizon Therapeutics Public has a PEG Ratio of 3.86. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Horizon Therapeutics Public has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

HZNP Price History

30 days | 90 days | 365 days | Advanced Chart

HZNP Stock News Headlines

September 6, 2023 | marketbeat.com

3 Growth Stocks to Buy in September (HZNP)

As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings

September 1, 2023 | marketbeat.com

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (HZNP)

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

September 29, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 29, 2023 | americanbankingnews.com

Horizon Therapeutics Public (NASDAQ:HZNP) Hits New 12-Month High at $115.87

September 27, 2023 | americanbankingnews.com

Horizon Therapeutics Public (NASDAQ:HZNP) Upgraded at StockNews.com

September 26, 2023 | benzinga.com

Board Member at Horizon Therapeutics Exercises Options Worth $2.31M

September 26, 2023 | finance.yahoo.com

Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry

September 26, 2023 | americanbankingnews.com

Horizon Therapeutics Public Limited (NASDAQ:HZNP) Given Consensus Rating of "Hold" by Analysts

September 29, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

September 26, 2023 | americanbankingnews.com

Horizon Therapeutics Public Limited (NASDAQ:HZNP) Receives $110.71 Average Target Price from Analysts

September 19, 2023 | finance.yahoo.com

Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List

September 19, 2023 | finance.yahoo.com

Health care: FTC Chair Lina Khan to crack down on 'below radar' deals

September 13, 2023 | finance.yahoo.com

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

September 5, 2023 | finance.yahoo.com

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

September 4, 2023 | benzinga.com

Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today

September 1, 2023 | finanznachrichten.de

Horizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

August 28, 2023 | finance.yahoo.com

FTC suspends challenge to Amgen-Horizon Therapeutics deal

August 26, 2023 | reuters.com

US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics

August 23, 2023 | finance.yahoo.com

Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups

August 16, 2023 | seekingalpha.com

Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?

August 16, 2023 | seekingalpha.com

Improved Outlook For Horizon Therapeutics And Amgen

August 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)

August 9, 2023 | markets.businessinsider.com

Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright

August 8, 2023 | finance.yahoo.com

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

August 4, 2023 | finance.yahoo.com

Amgen raises full-year earnings and revenue outlook

August 3, 2023 | benzinga.com

Check Out What Whales Are Doing With HZNP

July 27, 2023 | finance.yahoo.com

Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients

See More Headlines

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:HZNP
CUSIP: 44047T10
CIK: 1492426
Web: www.horizontherapeutics.com
Phone: (531) 772-2100
Fax: 224-383-3001
Employees: 2,115
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $110.71
High Stock Price Forecast: $125.00
Low Stock Price Forecast: $74.00
Forecasted Upside/Downside: -4.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.87
Trailing P/E Ratio: 61.87
Forward P/E Ratio: 26.97
P/E Growth: 3.86
Net Income: $521.48 million
Net Margins: 12.02%
Pretax Margin: 12.18%
Return on Equity: 20.46%
Return on Assets: 11.52%

Debt

Debt-to-Equity Ratio: 0.48
Current Ratio: 4.27
Quick Ratio: 4.09

Sales & Book Value

Annual Sales: $3.64 billion
Price / Sales: 7.27
Cash Flow: $7.05 per share
Price / Cash Flow: 16.41
Book Value: $22.38 per share
Price / Book: 5.17

Miscellaneous

Outstanding Shares: 228,995,000
Free Float: 223,957,000
Market Cap: $26.49 billion
Optionable: Optionable
Beta: 1.05

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Timothy P. Walbert (Age 56)
Chairman, Pres & CEO
Comp: $3.5M

Mr. Aaron L. Cox (Age 40)
Exec. VP of Fin. & CFO
Comp: $1.36M

Mr. Sean M. Clayton J.D. (Age 44)
Exec. VP & Gen. Counsel
Comp: $7.03M

Mr. Andy Pasternak (Age 52)
Exec. VP & Chief Strategy Officer
Comp: $1.4M

Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)
Exec. VP of R&D
Comp: $3.66M

Mr. Patrick McIlvenny (Age 44)
Sr. VP & Chief Accounting Officer

Ms. Tina E. Ventura
Sr. VP & Chief Investor Relations Officer

Mr. Geoffrey M. Curtis (Age 48)
Exec. VP of Corp. Affairs & Chief Communications Officer

Ms. Keli Walbert
Exec. VP & Chief Marketing Officer

Ms. Jane Gonnerman
Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.
What is Horizon Therapeutics Public's stock price forecast for 2023?: 8 equities research analysts have issued twelve-month price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $74.00 to $125.00. On average, they anticipate the company's stock price to reach $110.71 in the next twelve months. This suggests that the stock has a possible downside of 4.3%.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.
How have HZNP shares performed in 2023?: Horizon Therapeutics Public's stock was trading at $113.80 at the start of the year. Since then, HZNP shares have increased by 1.7% and is now trading at $115.69.
View the best growth stocks for 2023 here.
Are investors shorting Horizon Therapeutics Public?: Horizon Therapeutics Public saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 7,100,000 shares, a decrease of 25.1% from the August 31st total of 9,480,000 shares. Based on an average daily trading volume, of 2,220,000 shares, the days-to-cover ratio is currently 3.2 days.
View Horizon Therapeutics Public's Short Interest.
When is Horizon Therapeutics Public's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our HZNP earnings forecast.
How were Horizon Therapeutics Public's earnings last quarter?: Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 EPS for the quarter, beating analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. The company's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS.
What ETFs hold Horizon Therapeutics Public's stock?: ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco NASDAQ Next Gen 100 ETF (QQQJ) and Goldman Sachs Hedge Industry VIP ETF (GVIP).
What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?: 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).
What is Horizon Therapeutics Public's stock symbol?: Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."
How do I buy shares of Horizon Therapeutics Public?: Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Horizon Therapeutics Public's stock price today?: One share of HZNP stock can currently be purchased for approximately $115.69.
How much money does Horizon Therapeutics Public make?: Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $26.49 billion and generates $3.64 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.87 on an earnings per share basis.
How many employees does Horizon Therapeutics Public have?: The company employs 2,115 workers across the globe.
Does Horizon Therapeutics Public have any subsidiaries?: The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
How can I contact Horizon Therapeutics Public?: Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial